Safety and effectiveness profile of raloxifene in long-term, prospective, postmarketing surveillance

Journal of Bone and Mineral Metabolism

Volumn 30, Issue 6, 2012, Pages 674-682

  Iikuni, Noriko ^a   Hamaya, Etsuro ^b   Nihojima, Shigeru ^c   Yokoyama, Shunji ^c   Goto, Wakana ^d   Taketsuna, Masanori ^d   Miyauchi, Akimitsu ^e   Sowa, Hideaki ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Development Center of Excellence   (Japan)

^c CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^d Lilly Research Laboratories   (Japan)

^e Miyauchi Medical Center   (Japan)

Author keywords

Japanese; Osteoporosis; Raloxifene; SERM

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; RALOXIFENE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISEASE; ACUTE KIDNEY FAILURE; ADENOMA; AGED; ANEMIA; ANGINA PECTORIS; AORTA THROMBOSIS; ARTHRITIS; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BLOOD PRESSURE; BONE DENSITY; BONE MARROW METASTASIS; BONE NECROSIS; BONE TURNOVER; BRAIN HEMORRHAGE; BRAIN INFARCTION; BREAST CANCER; CATARACT; CEREBROVASCULAR ACCIDENT; CHOLELITHIASIS; CHRONIC KIDNEY FAILURE; COMPRESSION FRACTURE; CONSCIOUSNESS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG USE; DUODENUM DISEASE; EDEMA; FEMALE; FEMUR NECK FRACTURE; FOREARM FRACTURE; GASTRITIS; GASTROINTESTINAL DISEASE; HEART FAILURE; HEART INFARCTION; HEMORRHAGIC GASTRITIS; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPESTHESIA; ILEUS; INSOMNIA; JAPANESE; KIDNEY FAILURE; LARGE INTESTINE CANCER; LEG FRACTURE; LEUKEMIA; LIVER FUNCTION; LONG TERM CARE; LUNG EDEMA; LYMPHANGITIS; MAJOR CLINICAL STUDY; MELENA; MENOPAUSE; MULTIPLE MYELOMA; MUSCLE SPASM; NAUSEA; OUTCOME ASSESSMENT; OVARY CANCER; OVARY TUMOR; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PERITONEUM CANCER; POSTMARKETING SURVEILLANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RECURRENT CANCER; REFLUX ESOPHAGITIS; RIB FRACTURE; SCAR FORMATION; SICK SINUS SYNDROME; SIDE EFFECT; SPINE FRACTURE; STAPHYLOCOCCAL PNEUMONIA; STOMACH CANCER; STOMATITIS; THORAX PAIN; THROMBOCYTE COUNT; THROMBOPHLEBITIS; THROMBOSIS; UPPER ABDOMINAL PAIN; VENOUS THROMBOEMBOLISM; VULVA DISEASE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY; COLLAGEN TYPE I; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PEPTIDES; PRODUCT SURVEILLANCE, POSTMARKETING; RALOXIFENE;

EID: 84875810993     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-012-0365-1     Document Type: Article

References (19)

1. The Committee of Japanese guideline for the prevention and treatment of osteoporosis (2006) Life Science Publishing, Basel
2. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 18:637-645
3. Nakamura T, Liu JL, Morii H, Huang QR, Zhu HM, Qu Y, Hamaya E, Thiebaud D (2006) Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis. J Bone Miner Metab 24:414-418
4. Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, Sarkar S, Harper K (2003) Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporosis Int 14:793-800
5. Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research, (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331-337
6. ® [US Package Insert 1/2011]. Indianapolis, IN: Eli Lilly and Company; 2011. http://pi.lilly.com/us/evista-pi.pdf. Accessed 4th Nov 2011
7. Kayser J, Ettinger B, Pressman A (2001) Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen. Menopause 8:328-332
8. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb M, Wenger N (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125-137
9. Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright TJ, Helterbrand JD, Anderson PW (2001) Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 88:392-395
10. Uebayashi J (1995) Current medical practice of the treatment of deep thrombophlebitis and pulmonary embolism in special institutions in Japan. Research report in 1995 by the Ministry of Health and Welfare-sponsored Research Group of Blood Coagulation Abnormalities, pp 55-58
11. Urushihara H, Kikuchi N, Yamada M, Yoshiki F, Miyauchi A (2009) Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on post marketing surveillance. Menopause 16:971-977
12. Martino S, Disch D, Dowsett SA, Keech CA, Mershon J (2005) Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 21:1441-1452
13. Goldstein SR, Duvernoy CS, Calaf J, Adachi JD, Mershon JL, Dowsett S, Agnusdei D, Stuenkel C (2009) Raloxifene use in clinical practice: efficacy and safety. Menopause 16:413-421
14. Cosman F, Baz-Hecht M, Cushman M, Vardy MD, Cruz JD, Nieves JW, Zion M, Lindsay R (2005) Short-term effects of estrogen tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb Res 116:1-13
15. Nishizawa Y, Nakamura T, Shiraki M, Ohta H, Fukunaga H, Dowsett SA, Agnusdei D, Stuenkel CA (2006) Metabolic bone markers after treatment of raloxifene chloride for menopausal osteoporosis women (preliminary report). Osteoporosis Jpn 14:231-235
16. Qu Y, Wong M, Thiebaud D, Stock JL (2005) The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial. Curr Med Res Opin 21:1955-1959
17. Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K (2004) Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial. Chin Med J 117:1029-1035
18. Seeman E, Crans GG, Diez-Perez AA, Pinette KV, Delmas PD (2006) Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporosis Int 17:313-316
19. Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone (NY) 33:522-532